
Non-hormonal options for those with breast cancer are usually what we recommend. There are situations after therapy when testosterone is safe and effective.
NK3 Inhibitor the Most Effective Regimen
Veozah (fezolinetant) is not included in the guidelines of major oncology organizations, such as the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), or similar groups, for the treatment of hot flashes in breast cancer patients undergoing anti-estrogen therapy. Current guidelines emphasize non-hormonal management options due to the need to avoid estrogen-based therapies in this population. Recommended treatments typically include:
- Selective serotonin reuptake inhibitors (SSRIs) such as venlafaxine or paroxetine.
- Serotonin-norepinephrine reuptake inhibitors (SNRIs).
- Gabapentin or pregabalin.
- Clonidine.
Veozah, a non-hormonal medication targeting neurokinin-3 receptors, has gained attention for its role in managing vasomotor symptoms but is still being evaluated in breast cancer patients. Trials like the HIGHLIGHT 1 Phase III study aim to determine its safety and efficacy in women with hormone receptor-positive breast cancer on anti-estrogen therapy. These findings could shape future updates to clinical guidelines.
For now, oncologists are encouraged to use established non-hormonal therapies while awaiting conclusive data and potential guideline revisions.